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Abstract
Background: Depression and binge drinking behaviours are common clinical problems, which cause substantial
functional, economic and health impacts. These conditions peak in young adulthood, and commonly co-occur.
Comorbid depression and binge drinking are undertreated in young people, who are reluctant to seek help via
traditional pathways to care. The iTreAD project (internet Treatment for Alcohol and Depression) aims to provide
and evaluate internet-delivered monitoring and treatment programs for young people with depression and binge
drinking concerns.
Methods: Three hundred sixty nine participants will be recruited to the trial, and will be aged 18–30 years will be
eligible for the study if they report current symptoms of depression (score 5 or more on the depression subscale of the
Depression Anxiety Stress Scale) and concurrent binge drinking practices (5 or more standard drinks at least twice in
the prior month). Following screening and online baseline assessment, participants are randomised to: (a) online
monthly self-assessments, (b) online monthly self-assessments + 12-months of access to a 4 week online automated
cognitive behaviour therapy program for binge drinking and depression (DEAL); or (c) online monthly assessment +
DEAL + 12-months of access to a social networking site (Breathing Space). Independent, blind follow-up assessments
occur at 26, 39, 52 and 64-weeks post-baseline.
Discussion: The iTreAD project is the first randomised controlled trial combining online cognitive behaviour therapy,
social networking and online monitoring for young people reporting concerns with depression and binge drinking.
These treatments represent low-cost, wide-reach youth-appropriate treatment, which will have significantly public
health implications for service design, delivery and health policy for this important age group.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12614000310662. Date registered 24
March 2014.
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Background
Adolescence and young adulthood represents a critical
period of development in which health and social behav-
iours are established. During this time, young people
acquire a wide range of skills and behaviours via their
family, social and community environments, and these
influences will affect their physical, psychological and
social health throughout their lives [1]. Early drinking
during this period poses a risk later in life, with binge
drinking during adolescence and young adulthood being
associated with a 40–60 % increase in likelihood of
developing alcohol dependence, regardless of family
history [13]. Prevalence rates for alcohol use disorders in
Australia are some of the highest worldwide [2]. Incidence
rates for depression are much higher among young people
than in any other age group [1], and at least 50 % of young
people who experience a depressive episode will experi-
ence one or more recurrent episodes of depression [3].
Young people drink differently from adults. In Australia
and the USA, 90 % of alcohol consumption in young
people occurs in the form of binge drinking 5 or more
standard drinks in one sitting, [4]. Epidemiological data
indicate that binge drinking peaks at age 19, with the aim
of getting drunk as quickly and cheaply as possible, in part
to cope with a range of emotional issues present at that
age [5]. Binge drinking in young people crosses all socio-
economic domains, and exerts its impact across all demo-
graphics and communities.
Mental disorders, particularly depression, will generally
emerge during adolescence and young adulthood, and
remain a significant challenge for our young people.
Australian data indicate that 1 in 4 people aged 16–24
years will experience a mental health disorder in a
12 month period, and up to 43 % report feeling sad for at
least 2 weeks in the past year [5]. Incidence rates for
depression are much higher among young people than in
any other age group, and at least 50 % of young people
who experience a depressive episode will experience one
or more recurrent episodes of depression [5].
Depression and binge drinking represent a lethal com-
bination for young people, as evidenced by higher rates
of land transport accidents and intentional self-harm
than in any other age group 2 in every 5 deaths, [1].
Binge drinking is a common correlate of road accidents,
and after a previous suicide attempt, depression is the
next highest risk factor for youth suicide [1]. Heavy alco-
hol use, including binge drinking, plays a role in both
the development and progression of mental disorders,
particularly depression [6].
Treatment access and retention of young people in
traditional treatments is poor
There is hope of full functional, physical and psycho-
logical recovery from the consequences of depression
and binge drinking. Animal models have shown that,
with abstinence from a period of heavy binge drinking,
neural stem-cell development can be re-instated, along
with the formation of new neurons and other brain cells
indicative of brain growth [7]. Effective treatment of
depression during early days of abstinence from binge
drinking can prevent the development of a depressive
episode, and in young mice has been shown to better
restore the ability of the brain to produce new cells [8].
In humans, psychological interventions, which allow
the exploration of links between disorders, are of likely
benefit to people with comorbid conditions, and are
worthy of closer development and testing, in light of the
potential for interactions between alcohol use and
pharmacotherapy [9]. Psychological treatment is often
preferred over pharmacotherapy [10], especially among
young people [11]. Good interpersonal relationships and
social connectedness have also been shown to exert a
significant protective effect on the development of
depression and in depressive and alcohol relapse [3, 12].
Despite this, treatment access for young people
remains a critical challenge for traditional mental health
and drug and alcohol services [13]. Patients under
25 years accounted for the least number of encounters
with a general practitioner 2008–9 in Australia (20 %),
representing a decrease in the frequency with which
this age group is accessing primary care services since
1999–00 [1]. Only 2 % of 15–24 year olds accessed a
psychologist in 2008–9, a rate that was half that of
their older counterparts [1]. Similar patterns were
seen for general counsellors.
How can we encourage young people into treatment?
In 2015, 73 %, of Australia’s population were Internet
users [14], with highest rates of access reported among
young people 93 %, [15]. The internet has become an
important source of health information for many people,
with evidence indicating that 71 % of young people aged
18–29 search for health-related information online [16].
After e-mail and using search engines, searching for
health information is the most popular online activity
for adults [17].
The increased availability and use of internet-based
programs as a supplement to health care is also a poten-
tial solution to well-documented treatment accessibility
problems [18], particularly among people with depres-
sion and AOD use comorbidity. Treatment can be
accessible at times and in locations that suit clients,
without the need to schedule appointments or to confront
the stigma associated with seeing a therapist. It offers priv-
acy and anonymity, and allows clients to work at their
own pace, tailoring the provision of information and strat-
egies. Interactive and multimedia options offer the poten-
tial for higher levels of engagement than other self-help
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modalities [23]. A recent meta-analysis of internet-based
interventions for alcohol misuse in adults revealed that
they are highly effective in reducing alcohol consumption,
and encouraging adherence to low-risk drinking guide-
lines [19]. Similarly in the depression field, internet-
delivered cognitive behaviour therapy has demonstrated
effectiveness in reducing depression, particularly when
combined with support from a therapist [20]. We have
previously demonstrated that, in an adult population,
computerised treatment for comorbid depression and al-
cohol use problems was effective in reducing both depres-
sion and alcohol use simultaneously, and produced similar
results to a face-to-face integrated intervention delivered
by a psychologist [21]. A recent systematic review of treat-
ments for co-occurring depression and substance use in
young people highlighted the promise of psychological
treatments targeting both issues simultaneously, and the
need for more innovative techniques, such as Internet-
based technologies, to better engage this group [22].
Social networking is also an increasingly popular on-
line activity for young people, and is most common for
Internet users in the younger age groups: 86 % of 18 to
24 year olds performed this activity in 2010–2011 [15].
Facebook is the most widely used of the social network-
ing sites, and in Australia there are currently over
10,000 000 Facebook users, representing 51 % of the
Australian population. The majority of these users are
young people 12 % for 13–17 years; 24 % for 18 to
24 years; 26 % for 25–34 years, [23]. Results of a 2011
Sensis® survey of 803 randomly selected Australians re-
ported that virtually all respondents aged under 30 (93 %)
used social networking sites, and the majority accessed
these sites every day [24]. Facebook is already frequently
used by patients, carers and healthcare professionals to
share their experiences with one another [25].
Given the popularity of social networking among
young people, there is opportunity for identification and
intervention regarding health behaviours particularly in
the adolescent and young adult population [26]. Social
support, integration, influence and social networks ap-
pear to play important roles in both behaviour change
and emotional health [27]. Peers are considered more in-
fluential than parents in their contribution to adolescent
binge drinking through such mechanisms as: modelling;
interpersonal persuasion; shaping norms, attitudes, and
values; and by providing opportunities and support for
problem drinking [28, 29]. As a result, social networking
websites have the potential to function as a platform for
promoting and establishing (positive and negative)
norms of behaviour among young people [30].
Aims
The internet Treatment for Alcohol and Depression
study (iTreAD, http://www.itread.com.au) will conduct
the first randomised controlled trial of an Internet-
delivered treatment for comorbid depression and binge
drinking in young people aged 18–30 years, augmented
with social networking support. We will examine the
relative impact of:
(a)Online monthly self-assessments for 12 months (OSA);
(b)OSA + 12-months of access to a 4-week program of
web-based intervention for binge drinking and
depressed mood (DEpression ALcohol, DEAL);
(c)OSA + DEAL + 12-months access to a purpose-built
social networking site (Breathing Space).
It is hypothesised that all groups will report reductions
in binge drinking frequency and depression over the
treatment period, but that this will be greatest for those
receiving DEAL. It is also hypothesised that participants
allocated to OSA +DEAL + Breathing Space will complete
more web-based sessions and therefore report superior
reductions in binge drinking frequency and depressive
symptoms relative to the other treatment conditions.
Primary hypothesis
(1) For binge drinking frequency and depression
(DASS21) scores at 64 weeks post-baseline, OSA +
DEAL + Breathing Space will have a superior impact
over the other conditions.
Secondary hypotheses
(2) Reductions in binge drinking frequency and DASS21
will occur at a faster rate in OSA +DEAL + Breathing
Space than the other treatment conditions; and
(3) Participants in OSA +DEAL + Breathing Space will
complete a greater number of DEAL sessions and
self-assessments, and report greater retention than the
other treatment conditions.
Design
The iTreAD study is a randomised controlled superiority
trial, with three parallel groups, and two primary end-
points (changes in depression and alcohol use between
baseline and 64-weeks post-baseline assessment). The
design is consistent with SPIRIT guidelines for clinical
trials [31]. Ethics approval has been obtained from the
University of New South Wales Human Research Ethics
Committee (Approval #HC13299) as the primary site.
Study setting
Participants will be sought across Australia, via online
recruitment strategies (e.g. Facebook, Twitter, Google
advertisements, other social media and online forums)
and traditional methods (e.g. University campuses, gen-
eral practitioner surgeries, health service settings, event
location promotion). Screening, assessment, treatment
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and follow-up phases will be conducted in the commu-
nity, via the Internet, at a time and location convenient
to the participants.
Inclusion and exclusion criteria
Inclusion criteria include: (1) aged 18–30 years; (2)
current depressive symptoms score at least 5 on the
DASS-Depression scale, [32]; (2) binge drinking at least
2 times in the previous month (≥5 standard drinks in
the one sitting), as measured by the Alcohol Use Disorders
Identification Test – consumption scale AUDIT-c, [33];
and (3) ability to access the Internet. Exclusion criteria are:
(1) psychotic symptoms lasting >2 days; (2) non-English
speakers; (3) people with organic brain diseases; and (4)
serious risk of suicide.
Participants
We will recruit 369 participants over a 24-month period
(16/month). The trial has a purposive sample of young
people reporting current binge drinking and comorbid
depressive mood.
Procedure
Initial contact with potential participants is by Internet,
whereby they complete an initial screening assessment
to determine eligibility and randomisation characteristics
as per CONSORT guidelines [34]. Eligible participants
receive an email link to online study information and
consent processes; with access to the full online baseline
assessment provided once consent is obtained. Randomisa-
tion to one of three treatment groups occurs upon online
assessment completion. Following randomisation, partici-
pants are provided their login access code along with
instructions about how to access the treatment website
and log in. Independent, blind follow-up occurs across all
conditions at 26, 39, and 52 and 64 weeks post-baseline.
Screening
In response to project advertisements, potential participants
complete an online screening tool that comprises the
following instruments:
(1)Entry criteria (age, Internet access);
(2)AUDIT-c [33];
(3)DASS21 [32];
(4)Expectations of Online Treatment Questionnaire [35];
(5)Independent/Interdependent Problem Solving
Questionnaire [36];
(6)Big 5 Inventory – Conscientiousness, Agreeableness,
Neuroticism [37].
Assessments
All assessment tools are widely administered in mental
health and alcohol research, and were chosen to maximise
compliance and minimise assessment burden (see
Table 1).
Demographics: information will include age, gender,
area of residence (urban/rural), education and occupation,
and ethnicity.
Service utilisation: includes self-reported hospitalisations,
emergency room visits, attendance at clinics, rehabilitation
programmes, contact with community mental health
teams, psychologists, psychiatrists, other health profes-
sionals, use of general practitioners, and use of medication
(including compliance). In addition, we will purchase
Medicare data on consenting participants to objectively
measure service utilisation throughout the treatment and
follow-up period.
Administration of follow-up assessments
The follow-up assessment team is located at a separate
University to the baseline/treatment team to maximise
blindness and independence. Follow-up assessors are
blind to treatment allocation and facilitate completion of
follow-up assessments via the Internet to all consenting
participants regardless of treatment participation.
Follow-up assessment occurs at 26, 39, 52 and 64 weeks
post-baseline. There is good evidence that web-based
assessments result in reliable and valid ratings of depres-
sive and alcohol use disorders [38].
In line with best practice standards and our previous
trial experience, the following strategies are employed to
maximise retention in treatment and assessment: (1)
obtain multiple contact modes at baseline; (2) rapid and
assertive response if contact is temporarily lost (e.g. within
24 h); (3) solicitation of consent to continued assessment
when participants wish to cease treatment; (4) negotiation
of a reduced set of assessment core measures (i.e. of
primary outcomes) when participants are unwilling to
undertake the full follow-up protocol; (5) $20 AUD
reimbursement for costs and time at baseline and a bonus
($20 AUD) for completing all scheduled follow-ups.
Interventions
Access to the treatment website for each of the following
conditions will be for a period of 12 months from the
point of randomisation.
(a)Online Monthly Self-assessment (see Table 1, all 369
participants): Participants access the self-assessments
from their preferred port for Internet access. Partici-
pants will receive an automated email prompt to log
onto the website to complete their self-assessments
at the required intervals. Information and referral to
relevant services will be provided on the website to
help the participant manage exacerbations in depressive
symptoms and alcohol misuse. Participants will have a
window of 2 weeks within which to complete each
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monthly self-assessment, before being designate as
non-adherent to that month. Invitations for subsequent
monthly assessments will occur regardless of previous
compliance, through until the 12-month timepoint.
There will be no further contact with the research
group until the independent, blind follow-up
commences.
(b)4 sessions of web-based intervention (246 participants):
Consists of 4 sessions of psychological treatment
delivered entirely via the Internet (DEAL), using the
preferred port for Internet access of the participants.
Access to the DEAL (DEpression ALcohol) interven-
tion is provided for a period of 12 months from
randomisation. Content of the DEAL sessions include
cognitive behaviour therapy (CBT) and motivational
strategies [39]. Participants are asked to complete each
session of the DEAL web-based intervention in se-
quence, a week apart, from the point of randomisation.
The website tracks participants’ progress through each
weekly module. In-built reminders prompt participants
to access the DEAL program after periods of inactivity.
Throughout the 12-month “treatment period” partici-
pants may review sessions of the DEAL program as
desired.
(c)Breathing Space (123 participants): Access to a
social networking community (Breathing Space) will
be provided to participants allocated to this
condition for a period of 12 months. The social
networking platform is provided by CafeWell
(Welltok Inc., https://www.cafewell.com), a web-
based and mobile app that integrates support for
behavioural and chronic health conditions, with
access to moderated mental health support communi-
ties. Breathing Space will be created as a closed
community on the CafeWell site, and moderated by
Australian research clinicians associated with the
project. During the hours of 9 am-9 pm, Australian
research clinicians will encourage participants to post
their thoughts, messages of support, update their
status, tell their stories, share self-assessment results,
and report on progress related to their mood and binge
drinking (successes and challenges). Outside of these
hours, USA-based coaches will monitor participants to
ensure any crisis situation and/or inappropriate posts
and situations are managed in a timely fashion. Notifi-
cations will be received via all participants’ nominated
email addresses and mobile app when any member
posts on the site, encouraging participants to view the
post. Participants will create their own profile and alias,
and will be encouraged not to use their real names. A
strict code of conduct has been developed for people
randomised to Breathing Space, which covers general
conduct, privacy, confidentiality, discussion of past
experiences, trauma and suicidal thoughts. The code
Table 1 Assessments and administration frequency
Assessment Instruments Baseline
Assessment
Interim Online Self-Assessments Independent Follow-up Assessment
4–52 weeks post-baseline 26, 39, 52 & 64 weeks post-baseline
Demographics ✓ - -
Service utilisation ✓ - ✓
Depression
DASS21 [32] ✓ ✓ ✓
Alcohol
AUDIT [33] ✓ - ✓
TLFB – Alcohol [45] ✓ ✓ (past 2 weeks) ✓ (past month)
Other
OTI – other drugs, energy drinks [46] ✓ - ✓
AQoL [47] ✓ - ✓
IPDEQ [48] ✓ - -
Reactive-Proactive Aggression [49] ✓ - ✓
Psychiatric Symptom Frequency [50] ✓ - ✓
List of Threatening Experiences [51] ✓ - ✓
Impact of Event Scale – Revised [52] ✓ - ✓
CIDI – PTSD items [53] ✓ - ✓
✓ -
Client Satisfaction with Treatment
CSQ [54] - - 64 weeks
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of conduct attempts to strike a balance between
allowing participants in the community to freely
express the thoughts and feelings of relevance to
them in a supportive and safe environment, whilst
minimising the potential for social contagion,
bullying, and other potentially damaging behaviours. In
addition, a clinical moderator manual has also been de-
veloped, to guide the nature and content of interactions
with participants in the Breathing Space community.
Randomisation
Randomisation will be conducted independently of the
study team, using an online program, which can only be
accessed after eligibility is confirmed. Allocation will be
on a 1:1:1 ratio, using permuted blocks of varying sizes
(e.g. 3, 9) and stratified for gender and antidepressant
status. Participants are advised of their treatment alloca-
tion once the study team is advised of their completed
online baseline assessment.
Primary endpoint
There are two primary endpoints: (1) depression at
64-weeks post-baseline, and (2) binge drinking frequency
at 64-weeks post-baseline.
Secondary endpoint
Secondary endpoints are at 64-weeks post-baseline, and
include alcohol use, anxiety (DASS-anxiety), service util-
isation, and quality of life (using the AQoL). Monthly
self-assessment data will be used to track the rate of
change in depressed mood and binge drinking frequency
between baseline and 12-months post-baseline (the
treatment period), to account for any change in symptoms
as a function of the baseline assessment session.
Statistical analysis plan
Data on screening, refusals and dropout are coded and
reported as per CONSORT guidelines, and primary ana-
lyses use intention-to-treat. Preliminary analyses compare
treatment groups for any baseline or health service utilisa-
tion differences using proportions for categorical variables
and means/standard deviations for continuous variables.
The primary outcomes will be compared between
groups at each time point using random effects linear re-
gression that includes data from all time points. Separate
models will be fitted for each outcome variable. The
models will include the fixed effects of treatment (Online
Monthly Self-assessment as referent category), time, the
interaction between treatment and time as well as the
baseline score and baseline score-by-time interaction. The
primary contrast will be the difference in least squares
means between treatment groups at week 64.
Since the standard errors for the fixed effects in the
model depend on the variance-covariance structure that
is used in the analysis, we will examine several possible
structures including models with random slopes and
intercepts, as well as a variety of error structures for the
repeated measures (compound symmetry, AR1, Toeplitz).
The model with the smallest Akaike Information Criterion
(AIC) will be selected as our final model.
The mixed model provides unbiased estimates of the
treatment effect under the assumption that data are
missing at random (MAR). Since the possibility of
non-ignorable missingness cannot be excluded, we
will conduct sensitivity analyses using non-ignorable
pattern-mixture and selection models to investigate
the robustness of our conclusions across these different
models for missing data.
Continuous secondary endpoints will be analysed using
the model described above, dichotomous secondary
endpoints will be modelled using logistic mixed models.
Sample size and power calculations
Our previous trials indicate approximately 25 % attrition
over a 52-week follow-up period [40]. Recruiting 123
participants per group (369 participants across 3 experi-
mental groups) and assuming an attrition rate of 30 %,
we anticipate having complete data from 87 participants
per group at 64 weeks (n = 261).
Our projected sample size at 64 weeks provides suffi-
cient statistical power (at the standard level of 0.80) to
detect differences between treatment groups of 0.25
standard deviations or greater, with a type 1 error rate of
2.5 %. Using baseline data from our previous studies
with the target population and the DEAL resource [41],
this corresponds to a difference between conditions of
1.3 drinks/day, or 9.4/week, and of 2.4 on the DASS21.
These differences are towards the lower limits of clinical
significance. However, within-condition changes are
likely to be substantial. Consistent with our previous re-
search, differences between treatment groups of <0.25SD,
provided there are equivalent retention rates and thera-
peutic alliance ratings, will not be considered clinically
significant.
Discussion
The iTreAD project focuses on a common clinical prob-
lem that causes substantial functional, economic, and
health impacts; comorbid depression and binge drinking.
These conditions are currently under-treated, contribute
significantly to the global disease burden and are at their
peak in young adulthood. Offering treatments of low
cost and with wide reach to affected people will address
current inequities of treatment access for these problems,
and provide a youth-appropriate modality of treatment
delivery. These results will have profound implications for
service design and health policy, and speak to important
questions about the nature of treatment effects in general.
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In commencing the iTreAD study and engaging our
study population, two key learnings have emerged,
resulting in changes to the study design and delivery to
better suit the needs of young people wanting to access
treatment (via our study) for depression and binge
drinking concerns.
(1)Participant preferences for contact
Our previous trials that have integrated Internet and
computerised interventions into the clinical
treatment of comorbid depression and addictive
disorders, suggested that real time therapist-support
was an influential factor in a potential participant’s
decision to enrol in the study [21, 42]. Regardless of
whether the treatment provided was entirely face-to-
face with a therapist, or supplemented with a
computerised treatment program, participants
have previously reflected that more face-to-face
support would have increased satisfaction with
treatment [43]. Accordingly, the iTreAD methodology
incorporated several points of “real-time” clinical con-
tact with participants (via phone). For the 18–30 year
age group, however, we have found the phone-based
contact requirement to be a barrier to participation.
For example, we had a significant proportion of
participants who were eligible, and completed their
online baseline assessment, but could not be
contacted via telephone to speak with a clinician
to complete their clinical interview, receive their
randomisation, and commence the study treatments.
Switching to a fully automated online consent and
assessment process has seen significantly better reten-
tion and participation by the young people engaged in
the trial to date, and progression through to random-
isation and treatment for those young people who
were unable to complete the phone-based ‘real time’
study phases.
(2)Duty of care considerations in non face-to-face trials
An important observation in the target population
for the iTreAD study is that, despite setting the
threshold for entry at relatively low levels of
depression and binge drinking behaviours, study
participants tend to be those reporting more severe
depressive symptoms and regular (daily) alcohol use.
By including additional optional mental health
domains in our baseline assessment, we have also
detected significant levels of exposure to traumatic
events, and high levels of current trauma symptoms.
This has presented an ethical and clinical challenge,
given the nation-wide recruitment strategy, and the
preference for non ‘real time’ contact by participants
in our study. It has taken the combination of our
expertise across Internet trials and significant clinical
expertise in working with people with severe
comorbidities to safely engage and support the
young people in our trial. The online format for
baseline assessment completion, whilst appealing to
the age group, has also potentially provided the ano-
nymity that might encourage higher levels of disclos-
ure of traumatic events, severe symptoms, and high-
risk behaviours than for traditional assessments. This
is an important advantage of the Internet, however
it also requires a considered and careful response to
participants in managing these disclosures. We have
thus devised a careful strategy to respond to these
disclosures, which involves a range of ‘real time’ op-
tions (phone calls, personalised private messaging),
and setting a threshold for self-report of suicidal and
traumatic symptoms that automatically triggers a
‘real time’ response. Having clinically trained staff
(e.g. clinical psychologists) is essential in these situa-
tions, as is regular clinical supervision sessions, and
access to ‘real time’ expertise to work through op-
tions for follow-up, referral, and engagement of local
crisis services to the participant should that be
indicated.
(3)Changes to the protocol since Clinical Trials
Registration
 Eligibility Criterion for Depression: We have set
eligibility for the current trial at a DASS-Depression
scale of 5 or greater to ensure we recruit partici-
pants with current levels of depressive symptoms.
Our clinical trials registration specifics an eligibility
criterion for the DASS of 12 or greater on the full
scale. This was modified as the criterion was not
specific or sensitive enough to recruit our target
sample.
 Removal of the Structured Clinical Interview for
DSM SCID, [44]. With removal of the phone-
based assessment, we also had to remove the
SCID-Depression and SCID-alcohol scales from
our baseline assessment, as these scales are not
currently validated for delivery in self-report
format. We will present SCID data on all partici-
pants who provided this information prior to the
implementation of full online baseline assessment.
 Statistical Analysis Plan: since completion of the
clinical trials registry, we have engaged the
independent expertise of a designated statistician
to develop the statistical analysis plan (and to
carry out said plan) for the current trial. The plan
reported in this study protocol is the analysis
plan that will be undertaken at the conclusion of
the study.
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